🇺🇸 FDA
Pipeline program

TENOFOVIR DISOPROXIL AND EMTRICITABINE , MK-8527 F1, Placebo for MK-8527, Placebo for Emtricitabine/Tenofovir Disoproxil

MK-8527-011

Phase 3 small_molecule active

Quick answer

TENOFOVIR DISOPROXIL AND EMTRICITABINE , MK-8527 F1, Placebo for MK-8527, Placebo for Emtricitabine/Tenofovir Disoproxil for HIV-1 prevention is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
HIV-1 prevention
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials